Meet Jerry McMahon

Jerry has spent more than 30 years working in biotechnology leadership, oncology R&D, venture capital, deal-making, and company building. His career includes senior roles at SUGEN/Pfizer, where he contributed to the development of protein kinase inhibitors including sunitinib, as well as leadership positions at MedImmune, Kolltan Pharmaceuticals, and Harpoon Therapeutics, which he built from an early-stage company through IPO and subsequent development collaborations.

Since joining STORM Therapeutics in September 2022, Jerry has helped position the company at the forefront of RNA epigenetics, a new area of small molecule drug discovery focused on RNA-modifying enzymes. Under his leadership, STORM has advanced one of the first inhibitors of an RNA-modifying enzyme into the clinic, opening a new route for targeting cancer biology through precise modulation of intracellular pathways.

“At STORM, we focus on targets within RNA-modifying pathways that are inherently suited to small molecule intervention. Advances in drug discovery technologies are improving how we identify and optimize these compounds, while deeper biological insight continues to reveal new, tractable targets where small molecules can deliver differentiated and scalable therapeutic benefit.”